Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART4215 plus talazoparib versus talazoparib alone in BRCA-mutated HER2-negative advanced breast cancer
MOH_2022-08-28_012005Phase 2Not yet recruiting
- Sponsor
- Artios Pharma
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing ART4215 with talazoparib with Talazoparib alone (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics of ART4215 and 1 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
art4215talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2022-08-28_012005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-28_012005.